Tilray Brands (NASDAQ: TLRY) just released its results for the third quarter of its fiscal 2024, and there’s nothing particularly objectionable in the data. Nevertheless, Tilray stock dropped 18% this morning, and investors may wonder whether there’s a prime bargain for the taking here.

Alternatively, Tilray stock might be “cheap for a reason,” as the old saying goes. Does the market perceive trouble ahead for Tilray Brands?

As always, I would encourage investors to rely on the actual data rather than on the fickle sentiment of short-term traders. That said, it’s important to try to figure out why the market is choosing not to partake of Tilray stock today.

A blue-chip canna-business

Every market sector has its blue-chip companies and stocks, including the cannabis-products sector. A decade ago, the bluest of the cannabis blue chips may have been Canopy Growth Corporation (NASDAQ: CGC).

However, Canopy isn’t the 800-pound gorilla in the room anymore. The ultimate blue-chip cannabis company would certainly be Tilray Brands, which owns Aphria, Hexo and Truss Beverages Company.

Aphria was a substantial canna-business in its own right, and Tilray is now a global juggernaut among cannabis companies. Thus, if Tilray is thriving, it’s a good sign for the sector as a whole.

Tilray and the rest of the cannabis market seemed to thrive in 2018. During that time, it felt like full legalization in the U.S. was right around the corner. Additionally, commentators were buzzing about so-called Cannabis 2.0, in which producers like Tilray were expected to make money hand over fist from ancillary cannabis products (a.k.a. “derivatives”) like vapes and edibles.

As it turned out, Cannabis 2.0 was more hype than reality. Secondary cannabis products didn’t turn out to be huge sellers like some investors hoped they would be. Furthermore, there was no massive tidal wave of cannabis decriminalization in the U.S.

Consequently, Tilray stock collapsed from $300 in 2018 to just $1.60 in mid-March. It was a devastating share-price collapse for canna-wealth hopefuls.

However, Tilray stock suddenly picked up steam during the past few weeks, rallying from $1.60 to $2.59 before tumbling this morning. To some extent, the share-price run-up may be attributed to the recent expansion of Tilray’s cannabis brands.

The primary catalyst though is probably the resurgence of hope for full cannabis legalization in the U.S. and elsewhere. Germany decriminalized cannabis for personal use, and Canada’s government is considering reducing the excise taxes on cannabis producers. Moreover, recent comments from U.S. Vice President Kamala Harris suggest that she favors reclassifying marijuana.

On top of all that, legalized marijuana use for recreational purposes will be on the ballot in Florida in November. Thus, given the aforementioned facts and catalysts, it certainly looks like a perfect storm is brewing, and Tilray stock ought to be flying higher.

Tilray stock tanks despite solid quarterly results

Additionally, Tilray just published its financial results for the third quarter of fiscal 2024, and there’s plenty of fodder for the bulls. If anything, Tilray’s results only point to growth and improvement.

Here’s what investors need to know. First of all, the company’s net revenue increased by roughly 30% to $188.3 million. A particular highlight for the quarter was Tilray’s beverage-alcohol net revenue, which soared 165% to $54.7 million. Perhaps then, there may be a renaissance in cannabis derivatives in 2024 — even if it didn’t happen in 2018.

At the same time, Tilray’s primary business, cannabis production, also brought a strong revenue stream. Notably, the company’s cannabis-segment net revenue grew 33% to $63.4 million in Q3 FY2024.

Additionally, Tilray’s adjusted gross profit increased 17% to $51.6 million. Frankly, I just couldn’t find anything in the company’s quarterly results to justify the share-price decline today. Tilray even managed to narrow its net earnings loss from $1.2 billion in the year-earlier quarter to just $105 million in the fiscal third quarter.

This begs the question of why Tilray dropped 18% this morning. I suspect that it’s just a hangover after the party, as the stock has rallied sharply over the past three weeks.

However, on a multi-year basis, Tilray stock is still down substantially. The company appears to be making progress toward profitability, and while there are no guarantees, changes may be coming in terms of cannabis legislation. Therefore, there’s still a long-term dip to be bought, and cannabis bulls might consider picking up a few Tilray shares for a small, speculative position. 

Share: Feed news

VALUEWALK LLC is not a registered or licensed investment advisor in any jurisdiction. Nothing on this website or related properties should be considered personalized investments advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. VALUEWALK LLC, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. The Company disclaims any liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.

Recommended content


Recommended content

Editors’ Picks

AUD/USD: Extra losses look likely below the 200-day SMA

AUD/USD: Extra losses look likely below the 200-day SMA

The bearish tone remained well in place in the risk complex, dragging AUD/USD to fresh multi-day lows in the sub-0.6600 region on the back of the strong bounce in the US Dollar.

AUD/USD News

EUR/USD puts 1.0800 to the test

EUR/USD puts 1.0800 to the test

The strong data-driven comeback in the Greenback forced EURUSD to revisit the 1.0800 neighbourhood, down for the fourth session in a row and trading at shouting distance from the 200-day SMA (1.0787).

EUR/USD News

Gold extends slide below $2,350.00

Gold extends slide below $2,350.00

Gold stays on the back foot and trades at its lowest level in over a week below $2,350. The benchmark 10-year US Treasury bond yield rises more than 1% following the stronger-than-forecast PMI data from the US, forcing XAU/USD to stretch lower.

Gold News

Ethereum reclaims $3,800, lawmakers urge SEC Chair to approve ETH ETF

Ethereum reclaims $3,800, lawmakers urge SEC Chair to approve ETH ETF

Ethereum (ETH) bounced back after a brief dip on Thursday as US lawmakers penned a letter to Securities & Exchange Commission (SEC) Chair Gary Gensler, urging him to approve spot ETH ETFs.

Read more

Is the Federal Reserve just winging it?

Is the Federal Reserve just winging it?

Are the central bankers at the Federal Reserve just winging it? It sure seems that way if you step back and take a long view of their decision-making. Fed officials project this aura of authority.

Read more

Forex MAJORS

Cryptocurrencies

Signatures